BJR open最新文献

{"title":"CT and MRI of head and neck cutaneous lesions.","authors":"Jason Gan,&nbsp;Romman Nourzaie,&nbsp;Brent J Doolan,&nbsp;Steve Connor","doi":"10.1259/bjro.20230006","DOIUrl":"https://doi.org/10.1259/bjro.20230006","url":null,"abstract":"<p><p>Cutaneous lesions are derived from the epidermis, dermis and cutaneous appendages. Whilst imaging may occasionally be performed to evaluate such lesions, they may be undiagnosed and demonstrated for the first time on head and neck imaging studies. Although usually amenable to clinical examination and biopsy, CT or MRI studies may also demonstrate characteristic imaging features which aid the radiological differential diagnosis. In addition, imaging studies define the extent and staging of malignant lesions, as well as the complications of benign lesions. It is important for the radiologist to understanding the clinical significance and associations of these cutaneous conditions. This pictorial review will describe and depict the imaging appearances of benign, malignant, overgrowth, blistering, appendage and syndromic cutaneous lesions. An increasing awareness of the imaging characteristics of cutaneous lesions and related conditions will help the framing of a clinically relevant report.</p>","PeriodicalId":72419,"journal":{"name":"BJR open","volume":"5 1","pages":"20230006"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9730151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proton linear energy transfer and variable relative biological effectiveness for adolescent patients with Hodgkin lymphoma.","authors":"Laura Ann Rechner,&nbsp;Maja V Maraldo,&nbsp;Edward Ak Smith,&nbsp;Anni Y Lundgaard,&nbsp;Lisa L Hjalgrim,&nbsp;Ranald I MacKay,&nbsp;Adam H Aitkenhead,&nbsp;Marianne C Aznar","doi":"10.1259/bjro.20230012","DOIUrl":"https://doi.org/10.1259/bjro.20230012","url":null,"abstract":"<p><strong>Objectives: </strong>Proton therapy has a theoretical dosimetric advantage due to the Bragg peak, but the linear energy transfer (LET), and therefore the relative biological effectiveness (RBE), increase at the end of range. For patients with Hodgkin lymphoma, the distal edge of beam is often located within or close to the heart, where elevated RBE would be of potential concern. The purpose of this study was to investigate the impact of RBE and the choice of beam arrangement for adolescent patients with mediastinal Hodgkin lymphoma.</p><p><strong>Methods: </strong>For three previously treated adolescent patients, proton plans with 1-3 fields were created to a prescribed dose of 19.8 Gy (RBE) in 11 fractions (Varian Eclipse v13.7), assuming an RBE of 1.1. Plans were recalculated using Monte-Carlo (Geant4 v10.3.3/Gate v8.1) to calculate dose-averaged LET. Variable RBE-weighted dose was calculated using the McNamara model, assuming an α/β ratio of 2 Gy for organs-at-risk.</p><p><strong>Results: </strong>Although the LET decreased as the number of fields increased, the difference in RBE-weighted dose (Δdose) to organs-at-risk did not consistently decrease. Δdose values varied by patient and organ and were mostly of the order of 0-3 Gy (RBE), with a worst-case of 4.75 Gy (RBE) in near-maximum dose to the left atrium for one plan.</p><p><strong>Conclusions: </strong>RBE-weighted doses to organs-at-risk are sensitive to the choice of RBE model, which is of particular concern for the heart.</p><p><strong>Advances in knowledge: </strong>There is a need to remain cautious when evaluating proton plans for Hodgkin lymphoma, especially when near-maximum doses to organs-at-risk are considered.</p>","PeriodicalId":72419,"journal":{"name":"BJR open","volume":"5 1","pages":"20230012"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10077416/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9327590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes following external beam radiotherapy to the prostate and pelvic lymph nodes in addition to androgen deprivation therapy in non-metastatic prostate adenocarcinoma with regional lymph node involvement: a retrospective cohort study.","authors":"Akmal Mohamad Roji,&nbsp;Rahul Sandhu,&nbsp;Anjali Zarkar","doi":"10.1259/bjro.20220030","DOIUrl":"https://doi.org/10.1259/bjro.20220030","url":null,"abstract":"<p><strong>Objective: </strong>There is a paucity of evidence for external beam radiotherapy (EBRT) in patients with non-metastatic prostate adenocarcinoma with regional lymph nodes (cN1) as primary treatment in addition to androgen deprivation therapy (ADT). We present the retrospective outcomes of cN1 patients treated with prostate and pelvic nodal (PPLN) EBRT and ADT.</p><p><strong>Methods: </strong>The clinical records of cN1 patients given PPLN EBRT from January 2012 to January 2020 were retrospectively reviewed. Primary outcomes of overall survival, prostate cancer-specific survival, and failure-free survival were analysed. Secondary outcomes of biochemical relapse-free survival, locoregional recurrence-free survival, and distant metastases-free survival were also reviewed. The prognostic values of clinicopathological parameters were investigated. Treatment toxicity was also reviewed.</p><p><strong>Results: </strong>We identified 121 cN1 patients treated with PPLN EBRT and ADT. Treatment was well tolerated, with only a minority (1.7%) having Grade 3 toxicities. 5-year overall survival and prostate cancer-specific survival were 74.4 and 89.1% respectively. 5-year failure-free survival was 55.4%; with 5-year biochemical relapse-free survival, locoregional recurrence-free survival, and distant metastases-free survival at 56.2%, 85.2%, and 65.4% respectively. The benefits of PPLN EBRT were seen in most patients, with prolonged failure-free period and good loco-regional control.</p><p><strong>Conclusion: </strong>Patients with cN1 disease should be considered for PPLN EBRT, in addition to ADT. Treatment is well tolerated with low toxicity, good locoregional control, and prolonged time to disease progression.</p><p><strong>Advances in knowledge: </strong>We report real-world experience of cN1 patients treated with PPLN EBRT in addition to ADT, with good outcomes following treatment and low toxicity.</p>","PeriodicalId":72419,"journal":{"name":"BJR open","volume":"5 1","pages":"20220030"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10077404/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9628471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response evaluation of two commercial thermoluminescence dosimeters (TLDs) against different parameters.","authors":"Sitah Fahad Alanazi,&nbsp;Haya Alarifi,&nbsp;Abdullah Alshehri,&nbsp;Mansour Almurayshid","doi":"10.1259/bjro.20220035","DOIUrl":"https://doi.org/10.1259/bjro.20220035","url":null,"abstract":"<p><strong>Objectives: </strong>It is essential to study the dosimetric performance and reliability of personal dosimeters. This study examines and compares the responses of two commercial thermoluminescence dosimeters (TLDs), the TLD-100 and the MTS-N.</p><p><strong>Methods: </strong>We compared the two TLDs to various parameters such as energy dependence, linearity, homogeneity, reproducibility, light sensitivity (zero point), angular dependence, and temperature effects using the IEC 61066 standard.</p><p><strong>Results: </strong>The results acquired showed that both TLD materials show linear behavior as indicated by the quality of the fit. In addition, the angular dependence results for both detectors show that all dose responses are within the range of acceptable values. However, the TLD-100 outperformed the MTS-N in terms of light sensitivity reproducibility for all detectors together, while the MTS-N outperforms the TLD-100 for each detector independently and that showed TLD-100 has more stability than MTS-N. The MTS-N shows better batch homogeneity (10.84%) than TLD-100 (13.65%). The effect of temperature in signal loss was clearer at higher temperature 65°C and it was however below ±30%.</p><p><strong>Conclusions: </strong>The overall results for dosimetric properties determined in terms of dose equivalents for all combinations of detectors are satisfactory. The MTS-N cards have better results in the energy dependence, angular dependency, batch homogeneity and less signal fading, whereas the TLD-100 cards are less sensitive to light and more reproducible.</p><p><strong>Advances in knowledge: </strong>Although previous studies showed several types of comparisons between TLDs, they have used limited parameters and different data analysis. This study has dealt with more comprehensive characterization methods and examinations combining TLD-100 and MTS-N cards.</p>","PeriodicalId":72419,"journal":{"name":"BJR open","volume":"5 1","pages":"20220035"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301716/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9736558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bibliometric analysis of the top 100 cited articles in breast radiology.","authors":"Tsz Ki Ko,&nbsp;Denise Jia Yun Tan","doi":"10.1259/bjro.20230027","DOIUrl":"https://doi.org/10.1259/bjro.20230027","url":null,"abstract":"<p><strong>Objective: </strong>Bibliometrics analysis is a widely used approach that enables influential research within specific fields to be identifiedTo identify the 100 most-cited articles in breast radiology and analyse the trend in breast imaging research.</p><p><strong>Methods and materials: </strong>A systematic search was conducted using the Thomson Rheuters Web of Science database. The results were ranked according to citation count and screened to create a single database. Data including first author, year of publication, journal, country of origin, primary institution, number of citations and average number of citations per year were extracted, as well as the impact factor and the 5-year impact factor of journals publishing the articles.</p><p><strong>Results: </strong>The systematic search yielded a total of 114,426 articles, after filters were applied to include papers that were available in English only. Citations for the 100 most-cited articles ranged from 515 to 3660. Half of the articles on the list were published between 2001 and 2010. Radiology has the most number of publications (<i>n</i> = 17), followed by JAMA-Journal of The American Medical Association (<i>n</i> = 9). CA-A Cancer Journal For Clinicians had the highest impact factor of 286.13. Mammogram (<i>n</i> = 49) was the most commonly studied modality, followed by Magnetic Resonance (<i>n</i> = 26). The most common topic of publication was diagnosis (<i>n</i> = 83).</p><p><strong>Conclusion: </strong>This research serves as a guide to the most influential articles on the topic of breast radiology.</p>","PeriodicalId":72419,"journal":{"name":"BJR open","volume":"5 1","pages":"20230027"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10121293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Common and uncommon lesions of the vulva and vagina on magnetic resonance imaging: correlations with pathological findings.","authors":"Yan Ning,&nbsp;Rennan Ling,&nbsp;Feiran Zhang,&nbsp;Guofu Zhang,&nbsp;He Zhang","doi":"10.1259/bjro.20230002","DOIUrl":"https://doi.org/10.1259/bjro.20230002","url":null,"abstract":"<p><p>Vulvar and vaginal lesions representing a wide spectrum of diseases in female lower genital tract diseases make up a small part of all gynecological etiologies. Many of them are rare etiologies and are reported in case-reports studies. Translabial and transperineal ultrasound are modalities of choice for the first evaluation of perineal lesions. MRI is usually performed to determine the etiology of the lesions and stage. Benign lesions of the vulva and vagina usually manifest as simple cystic (vestibular cyst or endometrioma) or solid lesions (leiomyoma or angiofibroblastoma), while malignancies usually appear as large, solid masses and fill into both vaginal and perineal area. Post-contrast images play an important role in establishing a differential diagnosis, however, some benign lesions can also exhibit a vivid enhancement. Knowledge about radiologic-associated pathological manifestations may aid clinicians in better understanding these pathologies, especially for some rare lesions, and making a proper diagnosis before invasive procedures.</p>","PeriodicalId":72419,"journal":{"name":"BJR open","volume":"5 1","pages":"20230002"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302693/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9794594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mucinous tumors arising from ovarian teratomas as another source of pseudomyxoma peritoneii: MR findings comparison with ovarian metastases from appendiceal mucinous tumors.","authors":"Yumiko Oishi Tanaka,&nbsp;Emiko Sugawara,&nbsp;Akiko Tonooka,&nbsp;Tsukasa Saida,&nbsp;Akiko Sakata,&nbsp;Yosuke Fukunaga,&nbsp;Hiroyuki Kanao,&nbsp;Toyomi Satoh,&nbsp;Masayuki Noguchi,&nbsp;Takashi Terauchi","doi":"10.1259/bjro.20220036","DOIUrl":"https://doi.org/10.1259/bjro.20220036","url":null,"abstract":"<p><strong>Objective: </strong>The origin of pseudomyxoma peritoneii (PMP) has been established as low-grade appendiceal mucinous tumors (AMT). However, intestinal-type ovarian mucinous tumors are known as another source of PMP. Recently, it is advocated that ovarian mucinous tumors causing PMP originates from teratomas. However, AMTs are often too small to detect on imaging; then, differentiating metastatic ovarian tumors of AMT from ovarian teratoma-associated mucinous tumors (OTAMT) is important. Therefore, this study investigates the MR characteristics of OTAMT compared to the ovarian metastasis of AMT.</p><p><strong>Methods: </strong>MR findings of six pathologically confirmed OTAMT were retrospectively analyzed compared to ovarian metastases of low-grade appendiceal mucinous neoplasms (LAMN). We studied the existence of PMP, uni- or bilateral disease, the maximum diameter of ovarian masses, the number of loculi, a variety of sizes and signal intensity of each content, the existence of the solid part, fat, calcification within the mass, and appendiceal diameters. All the findings were statistically analyzed using the Mann-Whitney test.</p><p><strong>Results: </strong>Four of the six OTAMT showed PMP. OTAMT showed unilateral disease, had a larger diameter, more frequent intratumoral fat, smaller appendiceal diameter than those in AMT, and they were statistically significant (<i>p</i> < .05). On the other hand, the number, variety of size, signal intensity of loculi, and the solid part, calcification within the mass did not differ from each other.</p><p><strong>Conclusion: </strong>Both OTAMT and ovarian metastasis of AMT appeared as multilocular cystic masses with relatively uniform signal and size of loculi. However, a larger unilateral disease with intratumoral fat and smaller size of the appendix may suggest OTAMT.</p><p><strong>Advances in knowledge: </strong>OTAMT can be another source of PMP, as AMT. MR characteristics of OTAMT were very similar to ovarian metastases of AMT; however, in cases with PMP combined with fat-containing multilocular cystic ovarian mass, we can diagnose them as OTAMT, not PMP caused by AMT.</p>","PeriodicalId":72419,"journal":{"name":"BJR open","volume":"5 1","pages":"20220036"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301709/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9730152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Should artificial intelligence have lower acceptable error rates than humans?","authors":"Anders Lenskjold,&nbsp;Janus Uhd Nybing,&nbsp;Charlotte Trampedach,&nbsp;Astrid Galsgaard,&nbsp;Mathias Willadsen Brejnebøl,&nbsp;Henriette Raaschou,&nbsp;Martin Høyer Rose,&nbsp;Mikael Boesen","doi":"10.1259/bjro.20220053","DOIUrl":"https://doi.org/10.1259/bjro.20220053","url":null,"abstract":"<p><p>The first patient was misclassified in the diagnostic conclusion according to a local clinical expert opinion in a new clinical implementation of a knee osteoarthritis artificial intelligence (AI) algorithm at Bispebjerg-Frederiksberg University Hospital, Copenhagen, Denmark. In preparation for the evaluation of the AI algorithm, the implementation team collaborated with internal and external partners to plan workflows, and the algorithm was externally validated. After the misclassification, the team was left wondering: what is an acceptable error rate for a low-risk AI diagnostic algorithm? A survey among employees at the Department of Radiology showed significantly lower acceptable error rates for AI (6.8 %) than humans (11.3 %). A general mistrust of AI could cause the discrepancy in acceptable errors. AI may have the disadvantage of limited social capital and likeability compared to human co-workers, and therefore, less potential for forgiveness. Future AI development and implementation require further investigation of the fear of AI's unknown errors to enhance the trustworthiness of perceiving AI as a co-worker. Benchmark tools, transparency, and explainability are also needed to evaluate AI algorithms in clinical implementations to ensure acceptable performance.</p>","PeriodicalId":72419,"journal":{"name":"BJR open","volume":"5 1","pages":"20220053"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301708/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9736566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diffusion kurtosis imaging as a biomarker of breast cancer.","authors":"Maya Honda,&nbsp;Denis Le Bihan,&nbsp;Masako Kataoka,&nbsp;Mami Iima","doi":"10.1259/bjro.20220038","DOIUrl":"https://doi.org/10.1259/bjro.20220038","url":null,"abstract":"<p><p>Diffusion kurtosis imaging (DKI) is a diffusion-weighted imaging method that describes non-Gaussian signal behavior using a relatively simple mathematical model. A parameter, kurtosis K, describes the deviation of the diffusion signal decay from a Gaussian pattern. The deviation reflects the complexity of the tissue microstructure affecting water diffusion. Several studies have investigated the diagnostic performance of DKI in distinguishing malignant from benign breast lesions. DKI has been reported to correlate with subtypes and with several molecular and other factors related to the treatment and prognosis of breast cancer. Some technical considerations remain to be resolved for the clinical application of DKI in the breast.</p><p><strong>Advances in knowledge: </strong>DKI, which increases the sensitivity to complex tissue microstructure compared to standard DWI, has been applied in the breast, allowing to increase clinical performance in distinguishing malignant from benign lesions and in predicting prognosis or treatment response in breast cancer.</p>","PeriodicalId":72419,"journal":{"name":"BJR open","volume":"5 1","pages":"20220038"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10077411/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9628470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imaging 2-hydroxyglutarate and other brain oncometabolites pertinent to critical genomic alterations in brain tumors.","authors":"Teena Thomas,&nbsp;Sunitha Thakur,&nbsp;Robert Young","doi":"10.1259/bjro.20210070","DOIUrl":"https://doi.org/10.1259/bjro.20210070","url":null,"abstract":"<p><p>The 2021 World Health Organization (WHO) Classification of Tumors of the Central Nervous System (CNS) and recent smaller annual updates have shown that alterations in tumor genetics are essential to determining tumor diagnosis, biological activity, and potential treatment options. This review summarizes the most important mutations and oncometabolites, with a focus on the central role played by 2-hydroxyglutarate in isocitrate dehydrogenase mutant tumors, as well as their corresponding imaging counterparts using standard and advanced imaging techniques.</p>","PeriodicalId":72419,"journal":{"name":"BJR open","volume":"5 1","pages":"20210070"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10077413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9449649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}